Schedule A Under Canada's Natural Health Products Regulations: The Disease Claim Rules That Keep Catching NPN Holders Off Guard

One of the most reliable predictors of an NHP compliance problem in Canada is this: the manufacturer understands the Natural Health Products Regulations but hasn’t read Section 3 of the Food and Drugs Act recently. Schedule A sits in the parent legislation, quietly invalidating claim language that otherwise looks reasonable — and it continues to generate voluntary recalls, warning letters, and product removals for companies that genuinely thought they had their labels under control.

The problem isn’t ignorance of the rules exactly. Most quality and regulatory teams know that disease claims are restricted. The failures happen at the edges — in the gap between what the NHPR explicitly addresses and what the FDA’s older, broader prohibition actually covers. Here’s what that looks like in practice, and why the line between a compliant claim and a prohibited one is narrower than most teams expect.

What Schedule A of the Food and Drugs Act Actually Prohibits

Section 3(1) of the Food and Drugs Act (R.S.C. 1985, c. F-27) states that no person shall advertise any food, drug, cosmetic, or device for sale as a treatment, preventative, or cure for any of the diseases, disorders, or abnormal physical states listed in Schedule A. NHPs are classified as drugs under the FDA, so they’re fully subject to this provision — that classification hasn’t changed since the Natural Health Products Regulations (SOR/2003-196) were enacted more than two decades ago.

The Schedule A list covers more than 30 specific conditions, including cancer, diabetes, cardiovascular disease, hypertension, Parkinson’s disease, glaucoma, arteriosclerosis, thyroid disorders, leprosy, tuberculosis, and a range of communicable diseases listed under the Quarantine Act. Some of these feel obvious — no credible NHP company is claiming to cure tuberculosis in 2026. But diabetes and heart disease are where the majority of compliance failures cluster, because the supplement industry has spent decades developing creative ways to gesture at these conditions without technically naming them.

What makes the prohibition more complex than it first appears: the restriction applies to all advertising, not just physical product labels. Health Canada’s interpretation covers websites, social media content, in-store signage, product flyers, health practitioner leave-behinds, and even customer testimonials that the manufacturer reposts or links to. The standard isn’t purely literal. Health Canada applies a cumulative impression test — if the overall message of your marketing is that a product treats a Schedule A condition, enforcement doesn’t require finding the exact word “diabetes” on your panel. The combination of images, claim language, and context can establish a prohibited impression on its own.

The Section 3(2) Exception Most NHP Manufacturers Misread

Section 3(2) of the FDA created a specific carve-out for licensed NHPs. Under this provision, a Schedule A condition can be referenced in a product claim — but only if that specific claim language was evaluated and approved as part of the NPN application process. This is where the practical confusion begins.

The exception is narrow and claim-specific. If your NPN was licensed with the approved indication “helps maintain healthy blood sugar levels already within the normal range,” you can use those words. You cannot then adapt that language on your e-commerce product page to read “supports blood sugar management in people with type 2 diabetes” — that’s a Schedule A disease claim, and a valid NPN for the same product doesn’t protect you. The licence approves a specific set of words. It doesn’t grant general permission to characterize the product in relation to the listed condition.

Health Canada’s Compendium of Monographs is the most practical compliance anchor here. Monographed ingredients come with standardized claim language that has already been reviewed against Section 3 standards — sticking closely to that language is usually the fastest path through an NPN application and the safest position once the product is on shelf. Deviating from monograph wording requires an evidence justification at Level A, B, or C (using Health Canada’s evidence classification framework), and it opens the door to a Notice of Deficiency that can add months to your review timeline. Health Canada targets a 180-day review window for Class II NPN submissions under the NHPR — a NOD resets that clock.

Where the Compliance Failures Actually Happen

Most Schedule A violations don’t originate with a label. They originate downstream of it.

The label-to-marketing gap is the most common failure mode we encounter. An NPN application gets approved with appropriately worded claims. The regulatory team signs off. Then a marketing team writes website copy to “better communicate the benefits” — and that copy crosses the Section 3(1) line. The label is compliant. The website isn’t. Health Canada’s compliance monitoring program scans digital channels systematically, and the mismatch triggers enforcement. By this point, the company typically has significant inventory in market and retailer commitments in place.

Combination claims are the second most frequent source of problems. Two individually approved claim phrases, combined into a single sentence, can imply a Schedule A condition that neither phrase references alone. Consider: a licensed NHP might have separate approved claims for cardiovascular support and cholesterol management. Those claims, stacked together in a headline or a banner ad in a way that implies therapeutic benefit for heart disease patients, may constitute a Section 3 violation even though each individual phrase appeared in the licensed indication. This kind of recombination typically happens during packaging redesigns or campaign refreshes, when new marketing language is generated without re-engaging the regulatory team.

Third-party and retailer content is an underappreciated risk, particularly in the e-commerce channel. If a licensed retailer posts a customer testimonial on a product page that reads “I’ve been using this supplement and my cardiologist reduced my statin dose,” and the manufacturer links to that page or republishes the review, Health Canada may treat that as advertising a Schedule A condition. Amazon product listings are especially vulnerable — the manufacturer often doesn’t write the full listing description, and algorithmic content optimization by the retailer can introduce prohibited language without anyone on the brand side reviewing it.

The enforcement consequences are real and proportionate. Health Canada’s compliance and enforcement toolkit includes warning letters, voluntary recall requests under Section 21 of the FDA, mandatory recalls under Section 21.3, and referrals to the Health Products and Food Branch Inspectorate for formal investigation. Administrative monetary penalties are available under the FDA as amended, with maximum penalties reaching $5 million for serious or repeat violations. More practically, a voluntary recall of a mid-volume NHP — covering destroyed inventory, re-labelling costs, and regulatory fees for an amended submission — easily runs into six figures before the product is back on shelf.

A Practical Framework for Staying on the Right Side of Section 3

The core discipline is simple but requires organizational coordination: every piece of consumer-facing content must be reviewed against the approved NPN claims before it goes live. That sounds obvious. In practice, it breaks down because marketing timelines don’t naturally align with regulatory review cycles, and because the people writing website copy often don’t have direct access to the NPN licence document.

A few practices that consistently reduce Schedule A exposure:

Anchor marketing copy to the licensed indication. Write consumer-facing content by starting with the exact approved claim from the NPN and working outward from there, rather than writing aspirational benefits and trying to bring them within compliance after the fact. The latter approach consistently produces claim language that’s one editorial decision away from a Section 3 problem.

Audit digital touchpoints at least quarterly. Health Canada’s compliance monitoring is ongoing. A claim that went up during a product launch six months ago may still be indexed and visible — on your website, on retailer pages you don’t control directly, or in PDF materials that were uploaded and forgotten. Regular audits should include first-party web properties, Amazon and other marketplace listings, and any distributor or retailer digital content that references the brand.

Train marketing on what Schedule A is — not the NHPR details. Your marketing team doesn’t need to understand the mechanics of evidence classification or submission timelines. But they do need to know that specific disease conditions are restricted, which conditions are most relevant to your product category, and that claim language requires regulatory review before it publishes. Building that reflex is more valuable than producing detailed policy documentation that nobody reads.

Build claim review into your standard operating procedures for any content publication. If a piece of consumer-facing content references health benefits, it should require a regulatory sign-off step before it goes live — the same way financial claims require legal review in other industries. This SOP doesn’t need to be burdensome; for most routine content, a 24-hour review turnaround is realistic.

Health Canada’s NNHPD reviewers aren’t looking for reasons to deny claims that are otherwise supported by evidence. The NPN licensing framework was explicitly designed to create a pathway for evidence-based health claims that would otherwise be prohibited under Section 3(1) — that’s the whole point of Section 3(2). The companies that consistently have clean compliance records are the ones that treat claim language as a regulatory function from day one, with marketing working within those boundaries rather than around them.

If your regulatory team hasn’t reviewed your full digital footprint recently — website, marketplace listings, social media, retailer content — that review is worth scheduling before Health Canada’s compliance monitoring does it for you.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• Supplement and NHP Testing Services for the Canadian Market — Third-party lab testing that supports NPN applications and supplier qualification for Canadian manufacturers.
• EU Cosmetics and Health Product Regulatory Compliance — How European regulatory frameworks approach disease claims and health benefit restrictions compared to Canada’s NHPR.